1 of 1
Story summary
- India secures partial relief from the U.S. 100% tariff on certain patented imports.
- Specialty medicines and ingredients now receive zero duty, while generic drugs remain untaxed.
- Relief began July 31 for an initial list and expanded September 29 to additional firms.
- Zero-tariff carve-out covers drugs for rare diseases, nuclear medicine, plasma-derived, fertility, cell-gene, antibody-drug, and animal health.
- The U.S. is India’s biggest pharma market, with $10 billion shipments in FY ending March 2025.